MX2017015012A - Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. - Google Patents

Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.

Info

Publication number
MX2017015012A
MX2017015012A MX2017015012A MX2017015012A MX2017015012A MX 2017015012 A MX2017015012 A MX 2017015012A MX 2017015012 A MX2017015012 A MX 2017015012A MX 2017015012 A MX2017015012 A MX 2017015012A MX 2017015012 A MX2017015012 A MX 2017015012A
Authority
MX
Mexico
Prior art keywords
acne
magnesium
topical
taurine
prevention
Prior art date
Application number
MX2017015012A
Other languages
English (en)
Other versions
MX365366B (es
Inventor
Jean Profet Margaret
Original Assignee
Jean Profet Margaret
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jean Profet Margaret filed Critical Jean Profet Margaret
Publication of MX2017015012A publication Critical patent/MX2017015012A/es
Publication of MX365366B publication Critical patent/MX365366B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se describen composiciones tópicas y orales para tratar y/o prevenir el acné. Las composiciones incluyen cantidades efectivas de taurina y de magnesio, en donde las cantidades efectivas son suficientes para tratar y/o prevenir el acné. También se describe un método para tratar y/o prevenir el acné en un sujeto en necesidad del mismo. El método incluye administrar al sujeto composiciones tópicas y/u orales que incluyen taurina y magnesio en cantidades suficientes para tratar y/o prevenir el acné.
MX2017015012A 2015-06-17 2016-06-10 Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. MX365366B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180842P 2015-06-17 2015-06-17
PCT/US2016/037050 WO2016205089A1 (en) 2015-06-17 2016-06-10 Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne

Publications (2)

Publication Number Publication Date
MX2017015012A true MX2017015012A (es) 2018-08-15
MX365366B MX365366B (es) 2019-05-30

Family

ID=57546606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015012A MX365366B (es) 2015-06-17 2016-06-10 Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.

Country Status (9)

Country Link
US (2) US9795633B2 (es)
EP (1) EP3310366A4 (es)
JP (2) JP6657394B2 (es)
KR (2) KR102055492B1 (es)
CN (1) CN107708708A (es)
AU (1) AU2016278939B2 (es)
CA (1) CA2987293C (es)
MX (1) MX365366B (es)
WO (1) WO2016205089A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642877B1 (en) * 2016-01-06 2017-05-09 Kenneth O. Russell Method of administration of chromium and magnesium sulfate for treatment of acne
WO2016205089A1 (en) * 2015-06-17 2016-12-22 Profet Margaret Jean Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne
CN107049890B (zh) * 2017-06-27 2020-04-03 广东芭薇生物科技股份有限公司 一种具有舒缓抗粉刺功效的护肤品
KR102310566B1 (ko) * 2018-05-21 2021-10-08 랩앤피플주식회사 여드름 완화 및 예방용 패치
WO2019225948A1 (ko) * 2018-05-21 2019-11-28 랩앤피플주식회사 여드름 완화 및 예방용 패치
KR102651395B1 (ko) * 2018-07-05 2024-03-26 랩앤피플주식회사 여드름 완화 및 예방용 화장품 조성물
EP3738588A1 (en) * 2019-05-13 2020-11-18 Margaret Jean Profet Topical and oral formulations comprising taurine and magnesium for use in the treatment of rosacea
ES2917623T3 (es) * 2019-05-16 2022-07-11 Synapharm Ind Synthesis Compuesto y composición para uso en el tratamiento del síndrome premenstrual y/o del trastorno disfórico premenstrual
WO2020229443A1 (fr) * 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384751A1 (fr) 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
CN1126596A (zh) * 1995-01-11 1996-07-17 徐富中 一种治疗粉刺的制剂
US5776498A (en) 1995-11-06 1998-07-07 Nutrition 21 Magnesium taurate as an adjuvant to rapid thrombolytic therapy
US5582839A (en) 1995-04-18 1996-12-10 Nutrition 21 Magnesium taurate and other mineral taurates
US5962517A (en) * 1997-01-31 1999-10-05 Murad; Howard Pharmaceutical compositions and methods for treating acne
US6558656B2 (en) 2000-04-20 2003-05-06 Morris Mann Oral and topical compositions and methods related thereto in the treatment of acne
US20040039042A1 (en) * 2002-08-23 2004-02-26 Fleming Thomas E. Method of transdermal drug delivery
US20040214891A1 (en) 2003-04-22 2004-10-28 Janusz Marcinkiewicz Method for inhibiting pathogenic bacteria and fungi growth and microbicidal composition
US20050008684A1 (en) 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
US7258875B2 (en) 2003-12-04 2007-08-21 Chiou Consulting, Inc. Compositions and methods for topical treatment of skin infection
CA2558150A1 (en) * 2004-03-02 2005-09-15 Giuliani S.P.A. Composition for regulating the trophism of hair follicles and the cutaneous production of sebum and use thereof in androgenetic alopecia
US20060193922A1 (en) 2005-02-25 2006-08-31 Natalia Neikrug Compositions and methods for the treatment of acne
US7955610B2 (en) 2005-08-04 2011-06-07 National Science And Technology Development Agency Antimicrobial composition for topical application and a method thereof
AR062334A1 (es) 2006-08-11 2008-10-29 Panacea Biotec Ltd Particulas para suministrar ingredientes activos, proceso para hacerlas y composiciones de las mismas
CN102159216A (zh) * 2008-07-17 2011-08-17 G·莱维斯 用于痤疮治疗的方法和材料
DK2418945T3 (en) 2009-04-15 2019-02-25 Bmg Pharma S P A Mineral salt-sulfonic acid compositions and methods of use
US20140121188A1 (en) 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
KR20170018852A (ko) * 2014-07-01 2017-02-20 엔리케 샤콘 상처 치료를 위한 국소 조성물 및 방법
WO2016205089A1 (en) * 2015-06-17 2016-12-22 Profet Margaret Jean Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne

Also Published As

Publication number Publication date
JP6657394B2 (ja) 2020-03-04
WO2016205089A1 (en) 2016-12-22
AU2016278939B2 (en) 2018-11-08
AU2016278939A1 (en) 2017-12-07
US20160367596A1 (en) 2016-12-22
US9795633B2 (en) 2017-10-24
JP2018517787A (ja) 2018-07-05
EP3310366A1 (en) 2018-04-25
CN107708708A (zh) 2018-02-16
KR20180004202A (ko) 2018-01-10
EP3310366A4 (en) 2019-01-02
KR102055492B1 (ko) 2019-12-12
US10342823B2 (en) 2019-07-09
JP2020073587A (ja) 2020-05-14
MX365366B (es) 2019-05-30
US20180036340A1 (en) 2018-02-08
CA2987293C (en) 2020-11-03
CA2987293A1 (en) 2016-12-22
KR20190137971A (ko) 2019-12-11

Similar Documents

Publication Publication Date Title
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
TW201613578A (en) Pharmaceutical combinations
TN2015000255A1 (fr) Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.

Legal Events

Date Code Title Description
FG Grant or registration